Cargando…
Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool
DNA methylation represents a crucial mechanism of epigenetic regulation in hematologic malignancies. The methylation process is controlled by specific DNA methyl transferases and other regulators, which are often affected by genetic alterations. Global hypomethylation and hypermethylation of tumor s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820560/ https://www.ncbi.nlm.nih.gov/pubmed/36614080 http://dx.doi.org/10.3390/ijms24010633 |
_version_ | 1784865493238153216 |
---|---|
author | Kalinkova, Lenka Sevcikova, Aneta Stevurkova, Viola Fridrichova, Ivana Ciernikova, Sona |
author_facet | Kalinkova, Lenka Sevcikova, Aneta Stevurkova, Viola Fridrichova, Ivana Ciernikova, Sona |
author_sort | Kalinkova, Lenka |
collection | PubMed |
description | DNA methylation represents a crucial mechanism of epigenetic regulation in hematologic malignancies. The methylation process is controlled by specific DNA methyl transferases and other regulators, which are often affected by genetic alterations. Global hypomethylation and hypermethylation of tumor suppressor genes are associated with hematologic cancer development and progression. Several epi-drugs have been successfully implicated in the treatment of hematologic malignancies, including the hypomethylating agents (HMAs) decitabine and azacytidine. However, combinations with other treatment modalities and the discovery of new molecules are still the subject of research to increase sensitivity to anti-cancer therapies and improve patient outcomes. In this review, we summarized the main functions of DNA methylation regulators and genetic events leading to changes in methylation landscapes. We provide current knowledge about target genes with aberrant methylation levels in leukemias, myelodysplastic syndromes, and malignant lymphomas. Moreover, we provide an overview of the clinical trials, focused mainly on the combined therapy of HMAs with other treatments and its impact on adverse events, treatment efficacy, and survival rates among hematologic cancer patients. In the era of precision medicine, a transition from genes to their regulation opens up the possibility of an epigenetic-based approach as a diagnostic, prognostic, and therapeutic tool. |
format | Online Article Text |
id | pubmed-9820560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98205602023-01-07 Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool Kalinkova, Lenka Sevcikova, Aneta Stevurkova, Viola Fridrichova, Ivana Ciernikova, Sona Int J Mol Sci Review DNA methylation represents a crucial mechanism of epigenetic regulation in hematologic malignancies. The methylation process is controlled by specific DNA methyl transferases and other regulators, which are often affected by genetic alterations. Global hypomethylation and hypermethylation of tumor suppressor genes are associated with hematologic cancer development and progression. Several epi-drugs have been successfully implicated in the treatment of hematologic malignancies, including the hypomethylating agents (HMAs) decitabine and azacytidine. However, combinations with other treatment modalities and the discovery of new molecules are still the subject of research to increase sensitivity to anti-cancer therapies and improve patient outcomes. In this review, we summarized the main functions of DNA methylation regulators and genetic events leading to changes in methylation landscapes. We provide current knowledge about target genes with aberrant methylation levels in leukemias, myelodysplastic syndromes, and malignant lymphomas. Moreover, we provide an overview of the clinical trials, focused mainly on the combined therapy of HMAs with other treatments and its impact on adverse events, treatment efficacy, and survival rates among hematologic cancer patients. In the era of precision medicine, a transition from genes to their regulation opens up the possibility of an epigenetic-based approach as a diagnostic, prognostic, and therapeutic tool. MDPI 2022-12-30 /pmc/articles/PMC9820560/ /pubmed/36614080 http://dx.doi.org/10.3390/ijms24010633 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kalinkova, Lenka Sevcikova, Aneta Stevurkova, Viola Fridrichova, Ivana Ciernikova, Sona Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title | Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title_full | Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title_fullStr | Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title_full_unstemmed | Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title_short | Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool |
title_sort | targeting dna methylation in leukemia, myelodysplastic syndrome, and lymphoma: a potential diagnostic, prognostic, and therapeutic tool |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820560/ https://www.ncbi.nlm.nih.gov/pubmed/36614080 http://dx.doi.org/10.3390/ijms24010633 |
work_keys_str_mv | AT kalinkovalenka targetingdnamethylationinleukemiamyelodysplasticsyndromeandlymphomaapotentialdiagnosticprognosticandtherapeutictool AT sevcikovaaneta targetingdnamethylationinleukemiamyelodysplasticsyndromeandlymphomaapotentialdiagnosticprognosticandtherapeutictool AT stevurkovaviola targetingdnamethylationinleukemiamyelodysplasticsyndromeandlymphomaapotentialdiagnosticprognosticandtherapeutictool AT fridrichovaivana targetingdnamethylationinleukemiamyelodysplasticsyndromeandlymphomaapotentialdiagnosticprognosticandtherapeutictool AT ciernikovasona targetingdnamethylationinleukemiamyelodysplasticsyndromeandlymphomaapotentialdiagnosticprognosticandtherapeutictool |